Reynders McVeigh Capital Management’s AbbVie ABBV Stock Holding History

Reynders McVeigh Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.32M	Buy	29,052 +302	+1%	+$67K	0.32%	52
2025 Q4	$6.57M	Buy	28,750 +680	+2%	+$155K	0.31%	55
2025 Q3	$6.5M	Sell	28,070 -1,470	-5%	-$299K	0.3%	54
2025 Q2	$5.48M	Sell	29,540 -2,683	-8%	-$499K	0.27%	59
2025 Q1	$6.75M	Sell	32,223 -1,470	-4%	-$286K	0.38%	49
2024 Q4	$5.99M	Buy	33,693 +109	+0.3%	+$20K	0.32%	51
2024 Q3	$6.63M	Sell	33,584 -2,683	-7%	-$501K	0.35%	49
2024 Q2	$6.22M	Sell	36,267 -1,184	-3%	-$196K	0.35%	48
2024 Q1	$6.82M	Sell	37,451 -3,446	-8%	-$594K	0.39%	49
2023 Q4	$6.34M	Sell	40,897 -733	-2%	-$107K	0.4%	49
2023 Q3	$6.21M	Sell	41,630 -975	-2%	-$143K	0.43%	43
2023 Q2	$5.74M	Buy	42,605 +1,438	+3%	+$211K	0.38%	47
2023 Q1	$6.56M	Buy	41,167 +263	+0.6%	+$40.2K	0.45%	45
2022 Q4	$6.61M	Sell	40,904 -2,766	-6%	-$424K	0.49%	44
2022 Q3	$5.86M	Sell	43,670 -1,716	-4%	-$246K	0.46%	47
2022 Q2	$6.95M	Sell	45,386 -1,266	-3%	-$193K	0.52%	45
2022 Q1	$7.56M	Sell	46,652 -1,589	-3%	-$231K	0.46%	44
2021 Q4	$6.53M	Sell	48,241 -39	-0.1%	-$4.61K	0.37%	45
2021 Q3	$5.21M	Buy	48,280 +306	+0.6%	+$35K	0.32%	48
2021 Q2	$5.4M	Sell	47,974 -1,219	-2%	-$137K	0.33%	48
2021 Q1	$5.32M	Sell	49,193 -1,563	-3%	-$167K	0.35%	47
2020 Q4	$5.44M	Sell	50,756 -1,219	-2%	-$117K	0.37%	48
2020 Q3	$4.55M	Sell	51,975 -769	-1%	-$72.4K	0.35%	47
2020 Q2	$5.18M	Buy	52,744 +7,052	+15%	+$621K	0.45%	44
2020 Q1	$3.48M	Sell	45,692 -1,584	-3%	-$135K	0.4%	49
2019 Q4	$4.19M	Buy	47,276 +14,412	+44%	+$1.2M	0.4%	48
2019 Q3	$2.49M	Buy	32,864 +3,156	+11%	+$216K	0.27%	61
2019 Q2	$2.16M	Sell	29,708 -4,400	-13%	-$346K	0.23%	66
2019 Q1	$2.75M	Sell	34,108 -3,574	-9%	-$292K	0.3%	59
2018 Q4	$3.47M	Sell	37,682 -2,393	-6%	-$210K	0.46%	43
2018 Q3	$3.79M	Sell	40,075 -490	-1%	-$46.5K	0.45%	46
2018 Q2	$3.76M	Buy	40,565 +2,446	+6%	+$239K	0.48%	46
2018 Q1	$3.61M	Sell	38,119 -970	-2%	-$107K	0.46%	45
2017 Q4	$3.78M	Sell	39,089 -270	-0.7%	-$25.4K	0.5%	42
2017 Q3	$3.5M	Sell	39,359 -20	-0.1%	-$1.52K	0.46%	44
2017 Q2	$2.85M	Sell	39,379 -1,100	-3%	-$74K	0.38%	55
2017 Q1	$2.64M	Sell	40,479 -2,641	-6%	-$166K	0.36%	58
2016 Q4	$2.7M	Sell	43,120 -1,250	-3%	-$76.3K	0.38%	53
2016 Q3	$2.8M	Sell	44,370 -334	-0.7%	-$21.6K	0.41%	51
2016 Q2	$2.77M	Sell	44,704 -1,852	-4%	-$113K	0.4%	47
2016 Q1	$2.66M	Buy	46,556 +10,830	+30%	+$604K	0.39%	49
2015 Q4	$2.12M	Buy	35,726 +4,680	+15%	+$270K	0.35%	51
2015 Q3	$1.69M	Sell	31,046 -1,413	-4%	-$92K	0.29%	58
2015 Q2	$2.18M	Buy	32,459 +4,250	+15%	+$277K	0.36%	47
2015 Q1	$1.65M	Buy	28,209 +895	+3%	+$54.1K	0.28%	59
2014 Q4	$1.79M	Buy	27,314 +100	+0.4%	+$6.3K	0.31%	53
2014 Q3	$1.57M	Buy	27,214 +3,355	+14%	+$186K	0.3%	57
2014 Q2	$1.35M	Buy	23,859 +238	+1%	+$12.5K	0.31%	62
2014 Q1	$1.21M	Buy	23,621 +107	+0.5%	+$5.41K	0.29%	66
2013 Q4	$1.24M	Hold	23,514	–	–	0.31%	64
2013 Q3	$1.05M	Sell	23,514 -150	-0.6%	-$6.65K	0.29%	65
2013 Q2	$978K	Buy	+23,664	New	+$1.03M	0.29%	68

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Reynders McVeigh Capital Management's ABBV Position: Q1 2026 in Review

Reynders McVeigh Capital Management increased its AbbVie (ABBV) stake by 1.1% in Q1 2026, buying an estimated $67K and bringing the position to 29,052 shares worth $6.32M. The position accounts for 0.32% of the portfolio, ranked #52.

Reynders McVeigh Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.56M in Q1 2022. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Reynders McVeigh Capital Management held 29,052 shares of AbbVie worth $6.32M as of Q1 2026.
Reynders McVeigh Capital Management bought 302 AbbVie shares in Q1 2026, an estimated $67K.
AbbVie made up 0.32% of Reynders McVeigh Capital Management's portfolio in Q1 2026, its #52 holding.
Reynders McVeigh Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Reynders McVeigh Capital Management's AbbVie position peaked at $7.56M in Q1 2022.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Reynders McVeigh Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.